

# Clinical trials of BNP-guided management

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 heart failure

Trial	Treatments	Patients	Trials design and methods
<b>BNP-guided management vs control</b>			
<b>TIME CHF , 2009</b> n=251/248 follow-up:	intensive BNP-guided therapy versus standard symptom-guided therapy	patients with heart failure, with the specific inclusion of patients & iexcl;& Yacute;75 years of age	Parallel groups open
<b>PRIMA</b> n=174/171 follow-up: 702 days	NT-proBNP guided management versus clinically guided management	Patients admitted for worsening heart failure and with NT-proBNP decreasing during their admission	Parallel groups open the Netherlands
<b>PROTECT , 2009</b> [NCT00351390] n=NA follow-up:	natriuretic-peptide-guided therapy versus standard management	patients with NYHA class 2-4 heart failure, LVEF <40% , and history of at least one admission or outpatient diuretic dose increase for heart-failure destabilization in the previous six months	Parallel groups
<b>STARS-BNP , 2007</b> n=110/110 follow-up: 6 mo	BNP-guidance as a supplement to clinical judgment versus traditional approach	patients in NYHA functional class 2-3 with an LVEF <45% ; optimally treated with angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and diuretics by CHF specialists	Parallel groups open
<b>BATTLESCARRED , 2009</b> [ANZCTR12605000735651] n=121/122 follow-up: 3y	drug treatment directed by plasma NTproBNP for 2 years versus usual care	patients admitted to hospital for HF	Parallel groups open New Zealand
<b>STARBRITE , 2007</b> [NCT00484770] n=NA follow-up: 3 mo	BNP-guided treatment versus clinically based management	patients in NYHA class 3-4 and with an LVEF <35% ; enrolled prior to discharge following hospitalization for acute decompensation	Parallel groups open
<b>Troughton , 2000</b> n=33/36 follow-up: 9.5 mo (>6 mo)	BNP-guided treatment versus empirical trial-based therapy dictated by clinical acumen617Ow	patients with impaired systolic function (leftventricular ejection fraction <40% ) and symptomatic heart failure (New York Heart Association class IIIV); treated with ACE inhibitors, loop diuretic with or without digoxin	Parallel groups open UK

continued...

Trial	Treatments	Patients	Trials design and methods
<b>BASEL</b> <i>ongoing</i> [NCT00130611] n=NA follow-up: 3 months	BNP guided diagnostics and initial therapy versus control	patients presenting with acute dyspnea	Parallel groups Open
<b>van Kraaij</b> <i>ongoing</i> [NCT00149422] n=NA follow-up:	NT-proBNP guided treatment versus control	chronic congestive heart failure	Parallel groups single blind
<b>RABBIT</b> <i>ongoing</i> [NCT00206856] n=NA follow-up:	-	-	

More details and results :

- BNP guided management for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q271>

## References

### TIME CHF, 2009:

Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP JAMA 2009 Jan 28;301:383-92 [[19176440](#)] [10.1001/jama.2009.2](#)

### PRIMA, 0:

Luc Eurlings Can Pro-Brain Natriuretic Peptide Guided Therapy of Heart Failure Improve Heart Failure Morbidity and Mortality? Main Outcome of the PRIMA-Study ACC.09/i2, Orlando, FL, March 2009 [0]

Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, Lok DJ, Crijs HJ, van Kraaij DJ, de Jonge N, Meeder JG, Prins M, Pinto YM Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRO-brain-natriuretic peptide guided therapy of chronic heart failure IMPROVE heart failure morbidity and mortality?) study. J Am Coll Cardiol 2010;56:2090-100 [[21144969](#)] [10.1016/j.jacc.2010.07.030](#)

### PROTECT, 2009:

### STARS-BNP, 2007:

Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-9 [[17448376](#)]

### BATTLESCARRED, 2009:

Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, Richards AM NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 2006;8:532-8 [[16829189](#)]

Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM N-Terminal Pro-B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure Results From the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) Trial. J Am Coll Cardiol 2009 Dec 29;55:53-60 [[20117364](#)]

**STARBRITE, 2007:**

Shah MR, Califf RM, Nohria A, et al. STARBRITE: A randomized pilot trial of BNP-guided therapy in patients with advanced heart failure. [Abstract 2554] American Heart Association Scientific Sessions 2006; November 13, 2007

**Troughton, 2000:**

Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30 [[10791374](#)]

**BASEL, :**

ongoing trial NCT00130611

**van Kraaij, :**

ongoing trial NCT00149422

**RABBIT, :**

ongoing trial NCT00206856